Last reviewed · How we verify
Autologous serum
Autologous serum is a patient's own blood serum used topically to provide growth factors and immunomodulatory components that promote tissue healing and reduce inflammation.
Autologous serum is a patient's own blood serum used topically to provide growth factors and immunomodulatory components that promote tissue healing and reduce inflammation. Used for Severe dry eye syndrome/keratoconjunctivitis sicca, Ocular surface disease refractory to conventional therapy, Stevens-Johnson syndrome ocular complications.
At a glance
| Generic name | Autologous serum |
|---|---|
| Also known as | AS, GSA |
| Sponsor | Anita Syla Lokaj |
| Drug class | Autologous biological product |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Autologous serum eye drops are prepared from the patient's own blood serum and contain naturally occurring growth factors, immunoglobulins, and other bioactive molecules that mimic tears. When applied topically, these components promote epithelial cell proliferation, reduce inflammation, and support ocular surface healing. This approach is particularly useful in severe dry eye disease and other ocular surface disorders where conventional treatments are insufficient.
Approved indications
- Severe dry eye syndrome/keratoconjunctivitis sicca
- Ocular surface disease refractory to conventional therapy
- Stevens-Johnson syndrome ocular complications
- Graft-versus-host disease (ocular manifestations)
Common side effects
- Ocular irritation or discomfort
- Infection risk (from preparation/handling)
- Allergic reaction
Key clinical trials
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (PHASE1, PHASE2)
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission (PHASE3)
- Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. (PHASE3)
- Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS) (NA)
- Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PHASE2)
- Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder (NA)
- Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous serum CI brief — competitive landscape report
- Autologous serum updates RSS · CI watch RSS
- Anita Syla Lokaj portfolio CI